Sara Nayeem is a mother, investor, and advocate for the biomedical innovation ecosystem. Sara received her AB in Biology from Harvard University, and then went on to experiences that spanned the medical, financial, and entrepreneurial worlds. She worked as an investment banking analyst at Morgan Stanley while deferring medical school at Yale University.
Drawn to the business and policy aspects of medicine, she decided to pursue an MD / MBA at Yale, eventually going back into investment banking in Merrill Lynch’s healthcare group. Sara then found her way to venture capital at New Enterprise Associates, where she focuses on biopharmaceutical investments. On Twitter (@SaraNayeem) and as a board member of NPLB, the New England Venture Capital Association, and Incubate Coalition, Sara advocates for the innovation ecosystem, improved patient access to medical therapies, and diversity and inclusion in the biopharma industry.
Life Science Builders agree that society's payments for branded drugs must be a finite mortgage, oppose the rent extraction that is on the rise in the drug industry today, and stand with us in calling on Congress to pass Contractual Genericization.
Read more
